Curated News
By: NewsRamp Editorial Staff
December 18, 2025
Nutriband Clarifies Fentanyl Order, Unveils Abuse-Deterrent Patch with $200M Potential
TLDR
- Nutriband's AVERSA FENTANYL abuse-deterrent patch could capture $80-200M in annual U.S. sales, offering a competitive edge in the opioid market.
- Nutriband combines its AVERSA abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch to deter abuse while maintaining medical access for chronic pain patients.
- This technology reduces fentanyl patch abuse and accidental pediatric exposure, improving safety while ensuring access for severe chronic pain patients.
- Nutriband is developing the first abuse-deterrent opioid patch, addressing a critical gap in pain management with innovative transdermal technology.
Impact - Why it Matters
This news matters because it addresses a critical intersection of public health, regulatory policy, and medical innovation in the ongoing opioid crisis. The Trump Administration's designation of illicit fentanyl as a weapon of mass destruction highlights the severity of the drug epidemic, but it risks stigmatizing legitimate medical uses, potentially limiting access for patients with severe chronic pain who rely on FDA-approved fentanyl therapies. Nutriband's response and development of AVERSA™ FENTANYL offer a proactive solution: by creating an abuse-deterrent patch, the company aims to reduce the risks of misuse and accidental exposure that contribute to opioid-related deaths and injuries, which have devastated communities globally. This innovation could set a new standard for safer opioid delivery, benefiting patients, healthcare providers, and policymakers by providing a tool that maintains therapeutic efficacy while enhancing safety. For investors, it represents a significant market opportunity in a high-need sector, with potential sales up to $200 million annually. Ultimately, this development underscores the importance of balancing access to essential medications with robust safety measures, a key challenge in modern healthcare.
Summary
Nutriband Inc. (NASDAQ: NTRB), a pharmaceutical company specializing in transdermal drug delivery, has issued a statement clarifying the distinction between illicit fentanyl and medically prescribed fentanyl therapies. This clarification comes in response to a Trump Administration Executive Order designating illicit fentanyl and its precursor chemicals as weapons of mass destruction. The company emphasized that this order should not be conflated with FDA-approved prescription fentanyl therapies, such as transdermal fentanyl patches, which are produced under rigorous regulatory oversight and remain medically necessary for patients with severe chronic pain. The White House+1 order targets the illegal drug trade, not legitimate medical use, and Nutriband aims to ensure continued access for patients who rely on these critical pain management options.
Addressing significant public health concerns, Nutriband highlighted ongoing issues with transdermal fentanyl patch abuse and accidental pediatric exposure. To combat these risks, the company is partnering with Kindeva Drug Delivery to develop AVERSA™ FENTANYL, an innovative abuse-deterrent opioid patch. This product combines Nutriband's proprietary AVERSA™ abuse-deterrent technology with Kindeva's FDA-approved fentanyl patch. The technology is designed to prevent abuse, misuse, diversion, and accidental exposure while maintaining therapeutic efficacy for patients. Nutriband projects that AVERSA™ FENTANYL could become the first abuse-deterrent opioid patch on the market, with potential peak annual U.S. sales ranging from $80 million to $200 million. The company's initial focus is the U.S. market, with plans for broader availability in major global medical markets, reflecting its commitment to addressing opioid safety worldwide.
The development underscores Nutriband's role in advancing transdermal pharmaceutical products through its AVERSA™ technology, which can be integrated into various patches to enhance safety. For more details, investors and the public can view the full press release via the provided link. This initiative is part of Nutriband's broader strategy to innovate in pain management while aligning with regulatory efforts to curb the opioid crisis. By leveraging partnerships and cutting-edge technology, the company aims to balance patient access with public safety, positioning itself as a key player in the evolving landscape of opioid therapeutics and abuse prevention.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, Nutriband Clarifies Fentanyl Order, Unveils Abuse-Deterrent Patch with $200M Potential
